Immatics is a biotechnology company focused on developing targeted immunotherapies for cancer patients, particularly in treating solid tumors. The company combines the discovery of cancer immunotherapy targets with the development of specific T cell receptors to enable a robust immune response. Immatics' pipeline includes Adoptive Cell Therapies and TCR Bispecifics, and it collaborates with global leaders in the pharmaceutical industry. The company's mission is to advance its therapies to improve the lives of cancer patients, and it maintains a strong commitment to innovation in immunotherapy technologies.
Discovery of HLA-restricted tumor-associated peptides as cancer targets β’ Biomarkers β’ Immunomonitoring β’ Peptidomics & mass spectrometry β’ Standardized PBMC collection
September 15, 2024
Clinical Research Associate for cancer patient drug development at Immatics.
September 15, 2024
Immatics seeks a Clinical Research Associate to oversee clinical trial monitoring.
September 15, 2024
Oversee global clinical trial operations for cancer immunotherapies.